SAN DIEGO, Nov. 19 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that David Ramsay, Halozyme’s Vice President and Chief Financial Officer, will present at the Lazard Capital Markets Fourth Annual Healthcare Conference to be held at the Palace Hotel in New York on Tuesday, November 27, 2007 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time).
Interested parties can access a live audio webcast and slide presentation via the Internet by visiting the Investor Relations section of the Company’s Web site at http://www.halozyme.com. An archived presentation will be available on the Web site for 30 days following the presentation.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company’s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
dramsay@halozyme.com dmarkley@lhai.com
CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme
Therapeutics, Inc., +1-858-704-8260, dramsay@halozyme.com; or investor
relations, Don Markley of Lippert-Heilshorn & Associates, +1-310-691-7100,
dmarkley@lhai.com, for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com//
